Low-temperature laminar flow ward for the treatment of multidrug resistance Acinetobacter baumannii pneumonia
Zhitao Gong1,2, Jin Li, Hongliang Luo1,2
1Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Abstract:
This study was designed to investigate the effect of low-temperature laminar flow ward (LTLFW) on the Acinetobacter baumannii pneumonia (MDR-ABP) in neurosurgical intensive care unit (NICU) patients. We evaluated whether patients in a LTLFW had significantly improved clinical outcomes as compared to those in nonconstant-temperature NICU (room temperature). The association of temperature with the prevalence of ABP and A. baumannii isolates (ABI) found in NICU patients was specifically investigated. In vitro microbiological experiments were conducted to measure the proliferation, antibiotic sensitivity, and genomic profiles of A. baumannii (AB) that grew in variable temperatures. MDR-ABP patients in LTLFW had significantly improved outcomes than those in the room temperature NICU. In addition, the numbers of ABI were positively associated with mean ambient outdoor temperatures (P = 0.002), with the incidence of ABP and average numbers of ABI among NICU patients being substantially lower in the winter as compared to other seasons. However, there were no significant seasonal variations in the other strains of the top five bacteria. Consistent with these clinical observations, AB growing at 20°C and 25°C had significantly reduced viability and antibiotic resistance compared to those growing at 35°C. The expression of genes related to AB survival ability, drug resistance, and virulence also differed between AB growing at 20°C and those at 35°C. LTLFW is effective in promoting the recovery of MDR-ABP patients because low temperatures reduced the density and virulence of AB and enhanced the efficacy of antibiotics, likely at the genetic level.
Insights
Low-temperature laminar flow wards (LTLFW) improve outcomes for neurosurgical intensive care unit (NICU) patients with Acinetobacter baumannii pneumonia (MDR-ABP). Lower temperatures reduce bacterial virulence and enhance antibiotic effectiveness.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Environmental Microbiology
Background:
- Multidrug-resistant Acinetobacter baumannii pneumonia (MDR-ABP) is a significant threat in neurosurgical intensive care units (NICUs).
- Environmental factors, such as temperature, may influence the prevalence and severity of hospital-acquired infections.
- The efficacy of temperature control in mitigating bacterial infections within healthcare settings requires further investigation.
Purpose of the Study:
- To investigate the impact of low-temperature laminar flow wards (LTLFW) on clinical outcomes for MDR-ABP patients in NICUs.
- To determine the association between ambient temperature and the prevalence of Acinetobacter baumannii isolates (ABI) in NICU patients.
- To evaluate the in vitro effects of temperature on Acinetobacter baumannii (AB) proliferation, antibiotic sensitivity, and genomic profiles.
Main Methods:
- A comparative study of MDR-ABP patients in LTLFW versus standard room temperature NICUs.
- Correlation analysis of ABI prevalence with ambient outdoor temperatures and seasons.
- In vitro experiments assessing AB growth, antibiotic resistance, and gene expression at varying temperatures (20°C, 25°C, 35°C).
Main Results:
- Patients in LTLFW demonstrated significantly improved clinical outcomes compared to those in room temperature NICUs.
- ABI prevalence and the incidence of ABP were positively associated with higher ambient temperatures and more prevalent in warmer seasons.
- In vitro, AB exhibited reduced viability, lower antibiotic resistance, and altered gene expression at lower temperatures (20°C and 25°C) compared to 35°C.
Conclusions:
- LTLFW is an effective strategy for improving recovery in MDR-ABP patients.
- Lower temperatures demonstrably reduce Acinetobacter baumannii density and virulence.
- Temperature modulation may enhance antibiotic efficacy against MDR-ABP, potentially through genetic mechanisms, offering a novel approach to infection control.
More Related Videos
06:57Use of an Integrated Low-Flow Anesthetic Vaporizer, Ventilator, and Physiological Monitoring System for Rodents
Published on: July 9, 2020
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:23Acute Respiratory Failure-IV